- Home
- ATHA vs CXAI Comparison
ATHA vs CXAI Comparison
Compare ATHA & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- CXAI
- Stock Information
- Founded
- ATHA 2011
- CXAI N/A
- Country
- ATHA United States
- CXAI United States
- Employees
- ATHA N/A
- CXAI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- CXAI EDP Services
- Sector
- ATHA Health Care
- CXAI Technology
- Exchange
- ATHA Nasdaq
- CXAI Nasdaq
- Market Cap
- ATHA 21.0M
- CXAI 22.4M
- IPO Year
- ATHA 2020
- CXAI N/A
- Fundamental
- Price
- ATHA $0.29
- CXAI $1.15
- Analyst Decision
- ATHA Buy
- CXAI
- Analyst Count
- ATHA 4
- CXAI 0
- Target Price
- ATHA $11.25
- CXAI N/A
- AVG Volume (30 Days)
- ATHA 206.7K
- CXAI 6.2M
- Earning Date
- ATHA 05-14-2025
- CXAI 04-07-2025
- Dividend Yield
- ATHA N/A
- CXAI N/A
- EPS Growth
- ATHA N/A
- CXAI N/A
- EPS
- ATHA N/A
- CXAI N/A
- Revenue
- ATHA N/A
- CXAI $7,142,000.00
- Revenue This Year
- ATHA N/A
- CXAI $114.23
- Revenue Next Year
- ATHA N/A
- CXAI N/A
- P/E Ratio
- ATHA N/A
- CXAI N/A
- Revenue Growth
- ATHA N/A
- CXAI N/A
- 52 Week Low
- ATHA $0.22
- CXAI $0.76
- 52 Week High
- ATHA $3.67
- CXAI $5.43
- Technical
- Relative Strength Index (RSI)
- ATHA 49.02
- CXAI 54.37
- Support Level
- ATHA $0.22
- CXAI $1.03
- Resistance Level
- ATHA $0.30
- CXAI $1.17
- Average True Range (ATR)
- ATHA 0.03
- CXAI 0.17
- MACD
- ATHA 0.01
- CXAI 0.02
- Stochastic Oscillator
- ATHA 79.22
- CXAI 51.43
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.